Personal Login
|
Register
|
Email Alerts
Click Here to Access Your Company IP Login
Shopping Cart
(0)
NEW! Advanced Search (BETA)
Home
PTV Guide
PTV Channel
PTV News Review
PharmaDeals Review
The Business Report
The Regional Report
The Financial Report
Business Network
Register
About PTV
About PTV
Why Advertise with PTV?
Subscription Information
Contact Us
Careers
Conference Services
Technical Services
Production Services
Oxford Television Studios
PTV News Review
PharmaDeals Review
The Business Report
The Regional Report
The Financial Report
Business Network
Recent Episodes
Watch recent episodes on
PTV News Review
Sunshine Heart:
Kymab: Tom Shepherd
Brandon Capital
QRx Pharma Ltd:
Polytherics close
BIOTECanada: Peter
CM Capital: Mark
Prosensa: Luc
Benitec: Peter
Bionomics Ltd:
OrthoCell: Paul
GBS Venture
Molmed: Holger
Biosceptre: Cliff
Novo Nordisk: Tomas
Hybrigenics:
Gallus
AstraZeneca: Geoff
AusBiotech: Anna
TVG: Robert
European
BioVista Inc.
Children's Hospital
Astex
AstraZeneca: Shaun
Spinifex: CEO, Tom
Asmacure. CEO,
Genentech Inc:
BioCity CEO, Glenn
Pfizer Inc's Polly
BioBDx: Byron
The Promise of
Karin Bryskhe, CEO
Bob Coughlin, CEO
BIA Chairman, Tim
GSK: Mark Wilson
Dr. Jay Tischfield
William Prather, of
Cellzome: Tim
BiondVax
Invida: John Graham
Pfizer: Doug
Merck Research
IDA Ireland: Dave
Syntaxin: Melanie
DSM
Genentech`s James
Roche, Dan
The pharma and drug
Janssen
Psioxus CEO John
BayBio CEO Gail
Konstantinos
Patrick O'Reilley,
Alan Lewis, 2011
Anne Lane,
John Noble,
Francis Gurry,
Anthony Venturino,
Linda Chao of
Blair Jackson of
David Chiswell, CEO
Olivier Litzka of
Marc Van de Craen
Naiyin Wang
Roel Bulthuis of
Bryan Morton tells
Martin Heidecker of
Sunil Shah
Manuel
Martin Buckland
Takeda make a
Greg Wiederrecht,
Damian Maron, CEO
Tim Sparey, Head of
Gregory Moss Smith,
ACT: Accelerating
Henning Afflerbach,
Phillippe
Marco Boorsma
Roche's Approach to
Remi Delansorne,
Kevin Johnson,
Clifford Stocks
Ian Nicholson of
Joaquin Gomez of
Rentschler
BioIndustry
Francesco De
Lilly Ventures: Ed
Kerstin Valinder
Immutep`s
Telormedix’s
Christian Zhand
Finn Benned Hansen
Luc Dochez on why
Christelle Dagoneau
AusBio Conference
Susan Graff talks
China and Korea -
QRX Pharma: Finding
Andrew Bray
Deborah Rathjen
BioAngels: Dr John
AusBioTech: Dr Anna
BIO: Growth of
Merck & Co and
Immunovaccine`s
BioServe: One of
REGiMMUNE:
LivTech Inc: Dr.
JBA: Setsuo
Canbas: Takumi
MGH & BU: Steven
Roche Partnering:
MassBio: Robert
Chiome: Masa
EDB Group: Carola
Bioniche: Graeme
Seeding Labs: Nina
SIOGEN Biotech:
PharmaVentures
PharmaVentures
PharmaVentures CEO,
Cerenis
BIO Ventures for
London Technology
Reed Smith LLP:
Cancer Research
Bayer Schering
Grant Thornton:
Roche & Genentech:
BIO: Jim Greenwood
DSM Biologics:
DSM
DSM
CellCoTec: Ian
KryoTrans
Epistem: Matthew
Almac Sciences:
Domainex Ltd:
Takeda Research
Deals in a Downturn
Paul Capital
PolyTherics Ltd:
KBC Peel Hunt: The
ChinaBio LLC:
ASEBIO:
European Patent
Orion Corporation:
Aisling Capital:
BioCat: Funding and
Novartis Venture
Amgen Spain:
Invest in Spain:
Genoma España: The
Merck & Co.:
TVM Capital:
Roche: Deals,
GlaxoSmithKline:
Galapagos:
Grant Thornton: UK
Argos Therapeutics:
Living Cell
Ernst & Young: The
Novartis:
J.P. Morgan: The
Merck Serono:
Minomic: Innovative
Biota: Success With
Starpharma:
Manitoba STEM:
BIOTECanada: Why
Intersuisse
GBS Venture
Roche: Partnering
Bailard
PlantBio Trust:
Eli Lilly: The
The Hon Peter
Paul Cheever
Pfizer: An Ideal
Biosceptre: A New
Biotechnology in
Roche: What they
The Ewing Marion
Rexahn
Sutro Biopharma:
American Gene
The Michael J Fox
BioBay: Using
Fountain Medical
BayBio's year and
ChinaBio LLC: China
Approaching
Moving forward:
Aisling Capital:
Genentech: Becoming
MPM Capital: The
Celtic Pharma:
Thiakis’ origins,
TVM Capital:
Chroma
Stemgent: Fate,
MolMed’s Key
BIA: Bringing
BIA: Funding and
Part 1: Is the
Part 2: Is the
Part 1: The Golden
Part 2: The Golden
Merck Serono
Part 1: 2009 and
Part 2: 2009 and
Johnson & Johnson:
Pfizer’s
The New Merck
BIO and 2009 – the
InDex
sanofi-aventis’ New
Roche:Genentech
Part 1: The future
Part 2: The future
Part 3: The future
1. Out-licensing by
2. Out-licensing by
The credit crunch
The Gateway to
Immunocore &
The Wellcome Trust:
Biotica’s Balancing
Reinventing Roche’s
Burnham’s
Compugen’s Powers
Idera
Nicast’s New
GlobeImmune’s
SeraCare’s
KaloBios’
Hadasit
Oncolytics Biotech:
What’s Next For
How SkyePharma
The Allergan Model
Menarini’s Global
Will GSK’s
The Diversification
Pfizer and Wyeth’s
The EBD Group's
Genera Biosystems:
China’s Emergence
The Future of
Bristol-Myers
Biota Focuses on
Starpharma’s
Merck Goes Back to
Roche Seeks Out CNS
New Pharma Partner
Pfizer’s Investment
Was Biotech Failed
AusBiotech Evolves
How Government Can
Victorian
Takeda Strengthens
How Do Eli Lilly &
Oxford BioMedica:
Sir Michael Rawlins
Early Stage Spin
Novacta Biosystems:
Recent Deals
Cancer Research
PharmaVentures:
DuBiotech: The
Antisoma Plc
InterMed Discovery:
EGEN: A Research
Cellzome and
Xceleron: Changing
Polyphor Ltd:
Stemgent: Supplying
EBD Group: Carola
Artisan Draws
La Jolla
Paul Capital
BioInvent’s Deal
EuropaBio: Working
BIO: The Future